These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 28679655)

  • 1. Marketing of unproven stem cell-based interventions: A call to action.
    Sipp D; Caulfield T; Kaye J; Barfoot J; Blackburn C; Chan S; De Luca M; Kent A; McCabe C; Munsie M; Sleeboom-Faulkner M; Sugarman J; van Zimmeren E; Zarzeczny A; Rasko JEJ
    Sci Transl Med; 2017 Jul; 9(397):. PubMed ID: 28679655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. US clinics marketing unproven and unlicensed adipose-derived autologous stem cell interventions.
    Turner LG
    Regen Med; 2015 May; 10(4):397-402. PubMed ID: 26022761
    [No Abstract]   [Full Text] [Related]  

  • 3. Regulating the advertising and promotion of stem cell therapies.
    von Tigerstrom B
    Regen Med; 2017 Oct; 12(7):815-826. PubMed ID: 29112482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Untested, unproven, and unethical: the promotion and provision of autologous stem cell therapies in Australia.
    McLean AK; Stewart C; Kerridge I
    Stem Cell Res Ther; 2015 Feb; 6(1):33. PubMed ID: 25689404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges in the Regulation of Autologous Stem Cell Interventions in the United States.
    Sipp D
    Perspect Biol Med; 2018; 61(1):25-41. PubMed ID: 29805146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The direct-to-consumer market for stem cell-based interventions in Australia: exploring the experiences of patients.
    Waldby C; Hendl T; Kerridge I; Lipworth W; Lysaght T; Munsie M; Stewart C
    Regen Med; 2020 Jan; 15(1):1238-1249. PubMed ID: 32009513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Manufacturing, characterization and control of cell-based medicinal products: challenging paradigms toward commercial use.
    Salmikangas P; Menezes-Ferreira M; Reischl I; Tsiftsoglou A; Kyselovic J; Borg JJ; Ruiz S; Flory E; Trouvin JH; Celis P; Ancans J; Timon M; Pante G; Sladowski D; Lipnik-Stangelj M; Schneider CK
    Regen Med; 2015; 10(1):65-78. PubMed ID: 25562353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct-to-consumer stem cell marketing and regulatory responses.
    Sipp D
    Stem Cells Transl Med; 2013 Sep; 2(9):638-40. PubMed ID: 23934911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The unregulated commercialization of stem cell treatments: a global perspective.
    Sipp D
    Front Med; 2011 Dec; 5(4):348-55. PubMed ID: 21964637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploiting science? A systematic analysis of complementary and alternative medicine clinic websites' marketing of stem cell therapies.
    Murdoch B; Zarzeczny A; Caulfield T
    BMJ Open; 2018 Feb; 8(2):e019414. PubMed ID: 29490963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory and policy tools to address unproven stem cell interventions in Canada: the need for action.
    Caulfield T; Murdoch B
    BMC Med Ethics; 2019 Aug; 20(1):51. PubMed ID: 31383026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Turning the Tide on Unproven Cell-Based Interventions.
    Ikonomou L; Weiss DJ
    Chest; 2020 Apr; 157(4):774-775. PubMed ID: 32252930
    [No Abstract]   [Full Text] [Related]  

  • 13. Identity and ownership issues in the regulation of autologous cells.
    Sipp D
    Regen Med; 2017 Oct; 12(7):827-838. PubMed ID: 29115180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The US Direct-to-Consumer Marketplace for Autologous Stem Cell Interventions.
    Turner L
    Perspect Biol Med; 2018; 61(1):7-24. PubMed ID: 29805145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selling stem cell 'treatments' as research: prospective customer perspectives from crowdfunding campaigns.
    Snyder J; Turner L
    Regen Med; 2018 Jun; 13(4):375-384. PubMed ID: 29985757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Industry Responsibilities in Tackling Direct-to-Consumer Marketing of Unproven Stem Cell Treatments.
    Master Z; Fu W; Paciulli D; Sipp D
    Clin Pharmacol Ther; 2017 Aug; 102(2):177-179. PubMed ID: 28695633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in the stem cells marketplace--report from Select Biosciences Stem Cells 2012 Conference.
    Razvi E
    Regen Med; 2012 May; 7(3):291-4. PubMed ID: 22594323
    [No Abstract]   [Full Text] [Related]  

  • 18. The involvement of Canadian physicians in promoting and providing unproven and unapproved stem cell interventions.
    Ogbogu U; Du J; Koukio Y
    BMC Med Ethics; 2018 May; 19(1):32. PubMed ID: 29716594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unproven stem cell interventions: A global public health problem requiring global deliberation.
    Master Z; Matthews KRW; Abou-El-Enein M
    Stem Cell Reports; 2021 Jun; 16(6):1435-1445. PubMed ID: 34107243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions.
    Bauer G; Elsallab M; Abou-El-Enein M
    Stem Cells Transl Med; 2018 Sep; 7(9):676-685. PubMed ID: 30063299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.